Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 21, 2026
SmartFinancial (SMBK) Reports Q2 Net Income of $16.3 Million with EPS Beat

SmartFinancial (SMBK) Reports Q2 Net Income of $16.3 Million with EPS Beat

Key Takeaways

  • Net income rose to $16.3 million, or $0.96 per diluted share, up from $11.7 million, or $0.69 per share, in Q2 2025.
  • Operating earnings per diluted share reached $0.96, beating analyst estimates of $0.92.
  • Revenue totaled $55.9 million, compared with consensus expectations around $56.9 million.
  • Net income increased from $13.7 million, or $0.81 per share, in the prior quarter.
  • Management noted approximately 15% annualized loan growth and a tax-equivalent net interest margin of 3.52%.
  • Average earning assets reached $5.52 billion during the quarter.

Why These Results Matter for Regional Bank Investors

SmartFinancial, Inc. serves as the holding company for SmartBank and focuses on commercial banking services mainly in Tennessee and nearby markets. Quarterly updates like this one give a clear window into loan demand, net interest margin trends, credit quality, and how the company manages expenses in a regional banking setting. The year-over-year profit growth points to improving operating leverage and balance sheet expansion, while the sequential comparison helps assess ongoing momentum. These details also shape views on capital strength and the potential for future dividends.

From what I see, the consistent improvement across periods stands out as a positive sign for the franchise.

Breaking Down the Q2 2026 Numbers

For the second quarter ended June 30, 2026, SmartFinancial reported net income of $16.3 million, or $0.96 per diluted common share. That compared with $11.7 million, or $0.69 per diluted share, in the same quarter of 2025 and $13.7 million, or $0.81 per diluted share, in the first quarter of 2026. Operating earnings, a non-GAAP measure, came in at $16.3 million, or $0.96 per diluted share, which topped the $0.92 consensus estimate. Revenue reached $55.9 million. The company pointed to solid loan growth and stable net interest margin performance against an average earning asset base of $5.52 billion.

I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Market Reaction Following the Release

Shares of SMBK traded in a relatively narrow range after the after-market release on July 20, 2026. The earnings beat on the bottom line, along with the continued loan growth commentary, supported positive sentiment among investors focused on regional bank fundamentals. Analysts viewed the sequential earnings improvement and modest revenue variance as largely in line with expectations, considering typical seasonal factors.

Key Factors to Monitor Going Forward

Investors will pay close attention to management’s comments on loan pipeline strength and credit quality trends in upcoming quarters. Steady expansion of the loan book at a measured pace could support net interest income, while any changes in deposit costs or funding mix will affect net interest margin stability.

Expense discipline and potential efficiency gains from recent technology and branch optimization investments remain areas worth watching. Broader economic indicators, such as regional employment trends and commercial real estate conditions, could influence credit loss provisions and overall asset quality metrics.

Upcoming catalysts include the next quarterly update and any news on capital return strategies like dividends or share repurchases. Tracking shifts in average earning assets and the tax-equivalent net interest margin will offer more insight into earnings sustainability.

Using AI Tools to Support My Analysis

In my regular research routine, I turn to Tickeron’s AI Screener when I want to filter the market efficiently. It helps scan thousands of stocks and ETFs with customizable options for industry, market cap, technical indicators, price patterns, and performance metrics. This approach makes it easier to spot trade ideas, trending names, and breakout candidates compared with manual methods. The tool has become a practical part of how I cross-check sector comparisons and identify relevant opportunities. AI Screener

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SMBK

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


SMBK in downward trend: price expected to drop as it breaks its higher Bollinger Band on July 24, 2026

SMBK broke above its upper Bollinger Band on July 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 45 similar instances where the stock broke above the upper band. In of the 45 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SMBK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 15, 2026. You may want to consider a long position or call options on SMBK as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for SMBK just turned positive on July 22, 2026. Looking at past instances where SMBK's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SMBK advanced for three days, in of 280 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 248 cases where SMBK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 56, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SMBK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.563) is normal, around the industry mean (1.356). P/E Ratio (15.552) is within average values for comparable stocks, (24.445). SMBK's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.896). SMBK has a moderately low Dividend Yield (0.006) as compared to the industry average of (0.031). P/S Ratio (4.248) is also within normal values, averaging (3.864).

Notable companies

The most notable companies in this group are PNC Financial Services Group (NYSE:PNC), US Bancorp (NYSE:USB), Itau Unibanco Banco Holding SA (NYSE:ITUB), Deutsche Bank Aktiengesellschaft (NYSE:DB), Banco Bradesco SA (NYSE:BBD), Huntington Bancshares (NASDAQ:HBAN), Regions Financial Corp (NYSE:RF), KeyCorp (NYSE:KEY).

Industry description

Regional banks have a smaller reach than major banks, and cater mostly to one region of a country, such as a state or within a group of states. They offer services often similar – albeit with some limitations/smaller scale – compared to major banks. Taking deposits, making loans, mortgages, leases, credit cards , fund management, insurance and investment banking. SunTrust Banks, State Street Corp., M&T Bank Corp. are some examples of U.S. regional banks.

Market Cap

The average market capitalization across the Regional Banks Industry is 6.57B. The market cap for tickers in the group ranges from 10.73K to 142.82B. CIHHF holds the highest valuation in this group at 142.82B. The lowest valued company is ACBCQ at 10.73K.

High and low price notable news

The average weekly price growth across all stocks in the Regional Banks Industry was 1%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 10%. OPHC experienced the highest price growth at 28%, while BCBP experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the Regional Banks Industry was -2%. For the same stocks of the Industry, the average monthly volume growth was -8% and the average quarterly volume growth was -32%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 46
SMR Rating: 53
Profit Risk Rating: 55
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
SMBK
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a regional bank

Industry RegionalBanks

Profile
Details
Industry
Regional Banks
Address
5401 Kingston Pike
Phone
+1 865 437-5700
Employees
585
Web
https://www.smartfinancialinc.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.